DOCSLIB.ORG

Additions and Deletions to the Drug Product List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Additions and Deletions to the Drug Product List Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 06 : June 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE CAPSULE;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA TARO PHARM INDS LTD 300MG;50MG;40MG A 213046 001 Jul 01, 2020 Jun NEWA ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >D> AA GRANULES PHARMS 325MG;5MG A 211729 001 Jan 03, 2020 Jun DISC >A> @ 325MG;5MG A 211729 001 Jan 03, 2020 Jun DISC >D> AA 325MG;7.5MG A 211729 002 Jan 03, 2020 Jun DISC >A> @ 325MG;7.5MG A 211729 002 Jan 03, 2020 Jun DISC >D> AA 325MG;10MG A 211729 003 Jan 03, 2020 Jun DISC >A> @ 325MG;10MG A 211729 003 Jan 03, 2020 Jun DISC ACYCLOVIR SODIUM INJECTABLE;INJECTION ACYCLOVIR SODIUM >A> AP EXELA PHARMA SCS LLC EQ 50MG BASE/ML A 207919 001 Jun 17, 2020 Jun NEWA ADAPALENE GEL;TOPICAL ADAPALENE >A> AB ALEOR DERMACEUTICALS 0.3% A 213508 001 Jun 18, 2020 Jun NEWA >D> AIR POLYMER-TYPE A >D> FOAM;INTRAUTERINE >D> EXEM FOAM KIT >D> +! GISKIT 10ML N 212279 001 Nov 07, 2019 Jun DISC >A> + @ 10ML N 212279 001 Nov 07, 2019 Jun DISC ALBENDAZOLE TABLET;ORAL ALBENDAZOLE >A> AB LUPIN LTD 200MG A 211636 001 Jun 10, 2020 Jun NEWA ALPRAZOLAM TABLET;ORAL ALPRAZOLAM >D> AB OXFORD PHARMS 0.25MG A 078491 001 Sep 25, 2008 Jun DISC >A> @ 0.25MG A 078491 001 Sep 25, 2008 Jun DISC >D> AB 0.5MG A 078491 002 Sep 25, 2008 Jun DISC >A> @ 0.5MG A 078491 002 Sep 25, 2008 Jun DISC >D> AB 1MG A 078491 003 Sep 25, 2008 Jun DISC >A> @ 1MG A 078491 003 Sep 25, 2008 Jun DISC >D> AB 2MG A 078491 004 Dec 12, 2008 Jun DISC >A> @ 2MG A 078491 004 Dec 12, 2008 Jun DISC ALVIMOPAN CAPSULE;ORAL >D> ALVIMOPAN >D> AB WATSON LABS TEVA 12MG A 208295 001 Dec 19, 2019 Jun DISC >A> @ 12MG A 208295 001 Dec 19, 2019 Jun DISC ENTEREG >D> AB +! CUBIST PHARMS 12MG N 021775 001 May 20, 2008 Jun CTEC >A> +! 12MG N 021775 001 May 20, 2008 Jun CTEC AMANTADINE HYDROCHLORIDE CAPSULE;ORAL AMANTADINE HYDROCHLORIDE >D> AB BIONPHARMA INC 100MG A 078720 001 May 29, 2008 Jun CHRS >A> AB ! 100MG A 078720 001 May 29, 2008 Jun CHRS >D> AB ! SANDOZ 100MG A 071293 001 Feb 18, 1987 Jun CHRS >A> AB 100MG A 071293 001 Feb 18, 1987 Jun CHRS Page 1 of 20 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST AMLODIPINE BESYLATE TABLET;ORAL NORVASC >D> AB + PFIZER EQ 2.5MG BASE N 019787 001 Jul 31, 1992 Jun CAHN >D> AB + EQ 5MG BASE N 019787 002 Jul 31, 1992 Jun CAHN >D> AB +! EQ 10MG BASE N 019787 003 Jul 31, 1992 Jun CAHN >A> AB + UPJOHN EQ 2.5MG BASE N 019787 001 Jul 31, 1992 Jun CAHN >A> AB + EQ 5MG BASE N 019787 002 Jul 31, 1992 Jun CAHN >A> AB +! EQ 10MG BASE N 019787 003 Jul 31, 1992 Jun CAHN AMLODIPINE BESYLATE; VALSARTAN TABLET;ORAL AMLODIPINE BESYLATE AND VALSARTAN >D> AB PAR PHARM INC EQ 5MG BASE;160MG A 090011 001 Mar 28, 2013 Jun DISC >A> @ EQ 5MG BASE;160MG A 090011 001 Mar 28, 2013 Jun DISC >D> AB EQ 5MG BASE;320MG A 090011 003 Mar 28, 2013 Jun DISC >A> @ EQ 5MG BASE;320MG A 090011 003 Mar 28, 2013 Jun DISC >D> AB EQ 10MG BASE;160MG A 090011 002 Mar 28, 2013 Jun DISC >A> @ EQ 10MG BASE;160MG A 090011 002 Mar 28, 2013 Jun DISC >D> AB EQ 10MG BASE;320MG A 090011 004 Mar 28, 2013 Jun DISC >A> @ EQ 10MG BASE;320MG A 090011 004 Mar 28, 2013 Jun DISC AMOXICILLIN TABLET, CHEWABLE;ORAL AMOXICILLIN >A> AB HIKMA 125MG A 205274 001 Jun 25, 2020 Jun NEWA >A> AB 250MG A 205274 002 Jun 25, 2020 Jun NEWA >D> TEVA 125MG A 064013 002 Sep 11, 1995 Jun CTEC >A> AB 125MG A 064013 002 Sep 11, 1995 Jun CTEC >D> ! 250MG A 064013 001 Dec 22, 1992 Jun CTEC >A> AB ! 250MG A 064013 001 Dec 22, 1992 Jun CTEC AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE CAPSULE, EXTENDED RELEASE;ORAL DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE >A> AB MYLAN 1.25MG;1.25MG;1.25MG;1.25MG A 211876 001 Jun 24, 2020 Jun NEWA >A> AB 2.5MG;2.5MG;2.5MG;2.5MG A 211876 002 Jun 24, 2020 Jun NEWA >A> AB 3.75MG;3.75MG;3.75MG;3.75MG A 211876 003 Jun 24, 2020 Jun NEWA >A> AB 5MG;5MG;5MG;5MG A 211876 004 Jun 24, 2020 Jun NEWA >A> AB 6.25MG;6.25MG;6.25MG;6.25MG A 211876 005 Jun 24, 2020 Jun NEWA >A> AB 7.5MG;7.5MG;7.5MG;7.5MG A 211876 006 Jun 24, 2020 Jun NEWA APIXABAN TABLET;ORAL APIXABAN >D> AB MICRO LABS 2.5MG A 210013 001 Dec 23, 2019 Jun DISC >A> @ 2.5MG A 210013 001 Dec 23, 2019 Jun DISC >D> AB 5MG A 210013 002 Dec 23, 2019 Jun DISC >A> @ 5MG A 210013 002 Dec 23, 2019 Jun DISC ASPIRIN; OXYCODONE HYDROCHLORIDE TABLET;ORAL OXYCODONE AND ASPIRIN >D> AA ACTAVIS LABS FL INC 325MG;4.8355MG A 090084 001 Mar 22, 2011 Jun DISC >A> @ 325MG;4.8355MG A 090084 001 Mar 22, 2011 Jun DISC ATAZANAVIR SULFATE CAPSULE;ORAL ATAZANAVIR SULFATE >A> AB ZYDUS PHARMS EQ 150MG BASE A 210575 001 Jun 04, 2020 Jun NEWA >A> AB EQ 200MG BASE A 210575 002 Jun 04, 2020 Jun NEWA >A> AB EQ 300MG BASE A 210575 003 Jun 04, 2020 Jun NEWA ATENOLOL TABLET;ORAL ATENOLOL >A> AB HLTHCARE 25MG A 073026 002 May 01, 1992 Jun CMS1 >A> AB 50MG A 073026 003 Sep 17, 1991 Jun CMS1 Page 2 of 20 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ATORVASTATIN CALCIUM TABLET;ORAL ATORVASTATIN CALCIUM >A> AB PERRIGO R AND D EQ 10MG BASE A 208478 001 Jun 23, 2020 Jun NEWA >A> AB EQ 20MG BASE A 208478 002 Jun 23, 2020 Jun NEWA LIPITOR >D> AB + PFIZER EQ 10MG BASE N 020702 001 Dec 17, 1996 Jun CAHN >D> AB + EQ 20MG BASE N 020702 002 Dec 17, 1996 Jun CAHN >D> AB + EQ 40MG BASE N 020702 003 Dec 17, 1996 Jun CAHN >D> AB +! EQ 80MG BASE N 020702 004 Apr 07, 2000 Jun CAHN >A> AB + UPJOHN EQ 10MG BASE N 020702 001 Dec 17, 1996 Jun CAHN >A> AB + EQ 20MG BASE N 020702 002 Dec 17, 1996 Jun CAHN >A> AB + EQ 40MG BASE N 020702 003 Dec 17, 1996 Jun CAHN >A> AB +! EQ 80MG BASE N 020702 004 Apr 07, 2000 Jun CAHN AZACITIDINE POWDER;INTRAVENOUS, SUBCUTANEOUS AZACITIDINE >A> AP EUROHLTH INTL SARL 100MG/VIAL A 209337 001 Jun 08, 2020 Jun NEWA AZITHROMYCIN TABLET;ORAL AZITHROMYCIN >D> AB YUNG SHIN PHARM EQ 600MG BASE A 211068 001 May 08, 2020 Jun DISC >A> @ EQ 600MG BASE A 211068 001 May 08, 2020 Jun DISC BARIUM SULFATE SUSPENSION;ORAL >A> ENTERO VU 24% >A> +! BRACCO 24% (144GM/600ML) N 208143 008 May 29, 2020 Jun NEWA BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE TABLET;ORAL BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE >D> AB APOTEX 5MG;6.25MG A 078794 001 Aug 21, 2014 Jun DISC >A> @ 5MG;6.25MG A 078794 001 Aug 21, 2014 Jun DISC >D> AB 10MG;12.5MG A 078794 002 Aug 21, 2014 Jun DISC >A> @ 10MG;12.5MG A 078794 002 Aug 21, 2014 Jun DISC >D> AB 20MG;12.5MG A 078794 003 Aug 21, 2014 Jun DISC >A> @ 20MG;12.5MG A 078794 003 Aug 21, 2014 Jun DISC >D> AB 20MG;25MG A 078794 004 Aug 21, 2014 Jun DISC >A> @ 20MG;25MG A 078794 004 Aug 21, 2014 Jun DISC BETAMETHASONE DIPROPIONATE SPRAY;TOPICAL >A> BETAMETHASONE DIPROPIONATE >A> AB TARO PHARMS EQ 0.05% BASE/SPRAY A 211722 001 Jun 17, 2020 Jun NFTG >A> @ EQ 0.05% BASE/SPRAY A 211722 001 Jun 17, 2020 Jun DISC SERNIVO >D> +! ENCORE DERMAT EQ 0.05% BASE/SPRAY N 208079 001 Feb 05, 2016 Jun CFTG >A> AB +! EQ 0.05% BASE/SPRAY N 208079 001 Feb 05, 2016 Jun CFTG >A> +! EQ 0.05% BASE/SPRAY N 208079 001 Feb 05, 2016 Jun CTEC BEXAROTENE CAPSULE;ORAL BEXAROTENE >A> AB HIKMA 75MG A 203663 001 Jun 16, 2020 Jun NEWA BOSENTAN TABLET;ORAL BOSENTAN >D> AB CIPLA 62.5MG A 210342 001 Jan 03, 2020 Jun DISC >A> @ 62.5MG A 210342 001 Jan 03, 2020 Jun DISC >D> AB 125MG A 210342 002 Jan 03, 2020 Jun DISC >A> @ 125MG A 210342 002 Jan 03, 2020 Jun DISC Page 3 of 20 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST BRIMONIDINE TARTRATE SOLUTION/DROPS;OPHTHALMIC QOLIANA >D> AT SANDOZ INC 0.15% N 021764 001 May 22, 2006 Jun CRLD >A> AT + 0.15% N 021764 001 May 22, 2006 Jun CRLD >A> AT +! 0.15% N 021764 001 May 22, 2006 Jun CHRS BROMOCRIPTINE MESYLATE TABLET;ORAL BROMOCRIPTINE MESYLATE >D> AB MYLAN EQ 2.5MG BASE A 076962 001 Sep 24, 2004 Jun DISC >A> @ EQ 2.5MG BASE A 076962 001 Sep 24, 2004 Jun DISC BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE SYRUP;ORAL BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE >A> AA WES PHARMA INC 2MG/5ML;10MG/5ML;30MG/5ML A 211170 001 Jun 16, 2020 Jun NEWA BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE FILM;BUCCAL >D> BUNAVAIL >D> + BDSI EQ 2.1MG BASE;EQ 0.3MG BASE N 205637 001 Jun 06, 2014 Jun DISC >A> + @ EQ 2.1MG BASE;EQ 0.3MG BASE N 205637 001 Jun 06, 2014 Jun DISC >D> + EQ 4.2MG BASE;EQ 0.7MG BASE N 205637 002 Jun 06, 2014 Jun DISC >A> + @ EQ 4.2MG BASE;EQ 0.7MG BASE N 205637 002 Jun 06, 2014 Jun DISC >D> +! EQ 6.3MG BASE;EQ 1MG BASE N 205637 003 Jun 06, 2014 Jun DISC >A> + @ EQ 6.3MG BASE;EQ 1MG BASE N 205637 003 Jun 06, 2014 Jun DISC BUPROPION HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL BUPROPION HYDROCHLORIDE >D> @ YICHANG HUMANWELL 100MG A 211347 001 Oct 16, 2018 Jun CMFD >A> AB1 100MG A 211347 001 Oct 16, 2018 Jun CMFD >D> @ 150MG A 211347 002 Oct 16, 2018 Jun CMFD >A> AB1 150MG A 211347 002 Oct 16, 2018 Jun CMFD >D> @ 200MG A 211347 003 Oct 16, 2018 Jun CMFD >A> AB1 200MG A 211347 003 Oct 16, 2018 Jun CMFD >A> AB3 ZHEJIANG JUTAI PHARM 150MG A 211200 002 Apr 29, 2020 Jun NEWA BUSPIRONE HYDROCHLORIDE TABLET;ORAL BUSPIRONE HYDROCHLORIDE >A> AB AUROBINDO PHARMA LTD 7.5MG A 078246 005 Feb 21, 2020 Jun NEWA >D> AB MYLAN 7.5MG A 075467 002 Mar 28, 2001 Jun CHRS >A> AB ! 7.5MG A 075467 002 Mar 28, 2001 Jun CHRS CELECOXIB SOLUTION;ORAL ELYXYB >D> +! DR REDDYS 25MG/ML N 212157 001 May 05, 2020 Jun CAHN >A> +! 25MG/ML N 212157 001 May 05, 2020 Jun CAHN CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE CAPSULE;ORAL LIBRAX >A> +! BAUSCH 5MG;2.5MG N 012750 001 Sep 01, 1966 Jun CAHN >D> +! VALEANT
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • NORPRAMIN® (Desipramine Hydrochloride Tablets USP)
    NORPRAMIN® (desipramine hydrochloride tablets USP) Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of NORPRAMIN or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. NORPRAMIN is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.) DESCRIPTION NORPRAMIN® (desipramine hydrochloride USP) is an antidepressant drug of the tricyclic type, and is chemically: 5H-Dibenz[bƒ]azepine-5-propanamine,10,11-dihydro-N-methyl-, monohydrochloride. 1 Reference ID: 3536021 Inactive Ingredients The following inactive ingredients are contained in all dosage strengths: acacia, calcium carbonate, corn starch, D&C Red No. 30 and D&C Yellow No. 10 (except 10 mg and 150 mg), FD&C Blue No. 1 (except 25 mg, 75 mg, and 100 mg), hydrogenated soy oil, iron oxide, light mineral oil, magnesium stearate, mannitol, polyethylene glycol 8000, pregelatinized corn starch, sodium benzoate (except 150 mg), sucrose, talc, titanium dioxide, and other ingredients.
    [Show full text]
  • Sulfhydryl Reduction of Methylene Blue with Reference to Alterations in Malignant Neoplastic Disease
    Sulfhydryl Reduction of Methylene Blue With Reference to Alterations in Malignant Neoplastic Disease Maurice M. Black, M. D. (From the Department of Biochemistry, New York Medical College, New York 29, N. t;., and the Brooklyn Cancer Institute, Brooklyn 9, N. Y.) (Received for publication May 8, 1947) A significant decrease in methylene blue re- reactivity is less than half that of the cysteine. It is ducing power of plasma from patients with malig- noteworthy also that the resultant leuco mixture nant neoplastic disease was previously reported did not revert back to colored methylene blue on (1). At that time it was suggested that change in a cooling, as was the case with methylene blue re- reducing group of the albumin molecule was a duction by plasma. likely source of this alteration. Similar conclusions Similar relationships were investigated between were reported also by Savignac and associates (7) cysteine and different concentrations of methylene as the result of analogous studies. blue. As seen in Fig. 2, similar curves are obtained, In an attempt to evaluate the effect of the sulf- but the position of the curve on the graph varies hydryl group on the reduction of methylene blue, a with the concentration of the methylene blue used. study was undertaken with various compounds of It should be noted that there is no appreciable known -SH and S-S structures. In addition, an difference in the reducing time of methylene blue attempt was made to establish a standard method on varying the concentrations between 0.10 per of calibration of various lots of methylene blue, so cent and 0.2 per cent, although 0.08 per cent shows that more uniform results would be possible in the a decided difference.
    [Show full text]
  • Treatment of Methaemoglobinemia in Dogs Following Ingestion of Baits Containing PAPP
    Treatment of methaemoglobinemia in dogs following ingestion of baits containing PAPP Introduction A new toxin for wild dog and fox management has been released in Australia. Known as DOGABAIT and FOXECUTE®, the new baits contain the chemical para-aminopropiophenone (or ‘PAPP’), which induces methaemoglobinemia following ingestion. Veterinarians may be presented with cases of off-target poisoning of domestic pets, and so need to be aware of the mode of action of the toxin and its antidote, in order to attempt management of these cases. Foxecute bait dosage is 400mg and Dogabait dosage is 1000mg of PAPP. Knowing which of these baits has been accidentally ingested may help with clinical decision making and determination of appropriate antidote dosage. General considerations - methaemoglobinemia Methaemoglobin occurs as the result of oxidative damage to haemoglobin, which can be induced in cats and dogs by several chemicals, e.g. naphthalene (mothballs), onions and garlic (typically in dogs after a BBQ) and paracetamol (especially in cats).1,2 Local anaesthetics, such as benzocaine, can also cause significant methaemoglobinemia if not carefully administered.2,3 The chemical PAPP in the new baits bio-transforms in the liver of eutherian carnivores to a metabolite that rapidly oxidises haemoglobin to methaemoglobin. Clinical signs Clinical signs of methaemoglobinemia include lethargy, cyanosis, ataxia, unresponsiveness, unconsciousness and death. Blood containing high concentrations of methaemoglobin is chocolate brown in colour (Figure 1) and cannot transport oxygen efficiently. Minor amounts of methaemoglobin in the blood may be reduced back to active haemoglobin by innate enzyme systems. However, significant haemoglobin oxidation can disable oxygen transport to the point of hypoxia, anoxia, and death.
    [Show full text]
  • Possible Involvement of Nitric Oxide (NO) Signaling Pathway in the Anti- Depressant-Like Effect of MK-801(Dizocilpine), a NMDA R
    Indian Journal of Experimental Biology Vol. 46, March 2008, pp 164-170 Possible involvement of nitric oxide (NO) signaling pathway in the anti- depressant-like effect of MK-801(dizocilpine), a NMDA receptor antagonist in mouse forced swim test Ashish Dhir & SK Kulkarni* Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India Received 27 November 2007; revised 15 January 2008 L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) is an important signaling pathway involved in depression. With this information, the present study aimed to study the involvement of this signaling pathway in the antidepressant-like action of MK-801 (dizocilpine; N-methyl-d-aspartate receptor antagonist) in the mouse forced-swim test. Total immobility period was recorded in mouse forced swim test for 6 min. MK-801 (5-25 μg/kg., ip) produced a U- shaped curve in reducing the immobility period. The antidepressant-like effect of MK-801 (10 μg/kg, ip) was prevented by pretreatment with L-arginine (750 mg/kg, ip) [substrate for nitric oxide synthase (NOS)]. Pretreatment of mice with 7-nitroindazole (7-NI) (25 mg/kg, ip) [a specific neuronal nitric oxide synthase inhibitor] produced potentiation of the action of subeffective dose of MK-801 (5 μg/kg, ip). In addition, treatment of mice with methylene blue (10 mg/kg, ip) [direct inhibitor of both nitric oxide synthase and soluble guanylate cyclase] potentiated the effect of MK-801 (5 μg/kg, ip) in the forced-swim test. Further, the reduction in the immobility period elicited by MK-801 (10 μg/kg, ip) was also inhibited by pretreatment with sildenafil (5 mg/kg, ip) [phosphodiesterase 5 inhibitor].
    [Show full text]
  • Methylene Blue Methylene Blue (Tetramethylthionine Chloride) Is a Blue Dye That Is Used for the Treatment of Methemoglobinemia
    February 2015 Poison Center Hotline: 1-800-222-1222 The Maryland Poison Center’s Monthly Update: News, Advances, Information Methylene Blue Methylene blue (tetramethylthionine chloride) is a blue dye that is used for the treatment of methemoglobinemia. Methemoglobinemia is defined as a blood me- themoglobin level above 1% and can be caused by chemicals that oxidize Fe2+ to Fe3+ in hemoglobin. This oxidized form of hemoglobin is called methemoglobin and has poor oxygen carrying capacity. Causes include nitrites and nitrates (found in preserved meats and well water contaminated with fertilizer), local anesthetics (e.g. teething gels, benzocaine spray), aniline dyes, antimalarials, and dapsone. Inducers of methemoglobinemia are usually ingested rather than inhaled. Methylene blue is an effective antidote for methemoglobinemia due to its own oxidizing properties. It oxidizes NADPH, forming the reduced product leukometh- ylene blue. Leukomethylene blue in turn acts as a reducing agent converting me- themoglobin to hemoglobin and thus restoring oxygen carrying capacity. Meth- ylene blue is indicated in patients with symptomatic methemoglobinemia (e.g. cyanosis, dyspnea, confusion, seizures, coma, metabolic acidosis, dark or brown Did you know? blood), usually occurring at methemoglobin levels of >20-30%. Those with high Methylene blue has been used risk comorbidities (anemia, CHF, pneumonia, angina) may require methylene blue in the treatment of refractory at lower methemoglobin levels. shock? Dosing for methylene blue is 1-2 mg/kg (0.1 to 0.2 mL/kg) of a 1% solution admin- istered intravenously over five minutes. The neonatal dose is 0.3-1 mg/kg. Admin- There is evidence that methylene istration is followed by a 15mL-30mL fluid flush to reduce local pain, as IV meth- blue may be useful for the ylene blue is highly irritating to tissue.
    [Show full text]
  • Methylene Blue Administration During Cardio- Pulmonary Resuscitation and Early Reperfusion Pro- Tects Against Cortical Blood-Brain Barrier Disruption
    Methylene blue administration during cardio- pulmonary resuscitation and early reperfusion pro- tects against cortical blood-brain barrier disruption Miclescu Adriana, Sharma Hari Shanker, Cécile Martijn, Wiklund Lars Department of Surgical Sciences/Anaesthesiology and Critical Care Medi- cine, Uppsala University Hospital, SE-751 85 Uppsala, Sweden Objective: The present study was time. The immunohistochemistry designed to study the effects of car- analysis indicated less blood brain diac arrest and cardiopulmonary barrier disruption in the animals resuscitation (CPR) on blood-brain receiving MB (CA+MB group) barrier (BBB) permeability and sub- evidenced by decreased albumin sequent neurological injury. It also leakage (P<0.01), water content tests the cerebral effects of MB on (P=0.02), potassium (P=0.04), but the maintenance of BBB integrity, also decreased neuronal injury the production of nitric oxide (NO) (P<0.001) in this group in and regulation of nitric oxide syn- comparison with the group that was thases (NOS) in cerebral cortex. not treated with MB (CA-MB). Intervention: The control group (CA, Similarly, MB treatment reduced n=16) underwent 12 min cardiac nitrite/nitrate ratio (P=0.02), iNOS arrest without subsequent CPR, after expression (P<0.01), and nNOS which the brain of the animals was expression (P<0.01). removed immediately or after 15 and Conclusion: Cerebral edema, in- 30 min. The other two groups with 12 crease BBB permeability and neuro- min cardiac arrest and subsequent 8 logic injury are observed early in min CPR received either an infusion ischemia induced by cardiac arrest. of saline (CA-MB group, n=10) or an MB markedly reduced BBB disrup- infusion of saline with MB (CA+MB, tion and subsequent neurologic in- n= 12) started one minute after the jury.
    [Show full text]
  • Short Reports Continuous Infusion of Methylene Blue for Septic
    Postgrad Med J 1996; 72: 612 - 624 (© The Fellowship of Postgraduate Medicine, 1996 Short reports Postgrad Med J: first published as 10.1136/pgmj.72.852.612 on 1 October 1996. Downloaded from Continuous infusion of methylene blue for septic shock Glen Brown, David Frankl, Terry Phang Summary presented to a community hospital with a 10- Nitric oxide has been determined to be a day history of left-sided chest pain causing potential mediator of the haemodynamic shortness of breath. Chest X-ray on the day of changes associated with sepsis. The hae- presentation demonstrated a left lower lobe modynamic eects of nitric oxide can be consolidation and a left pleural effusion. The partially antagonised by methylene blue, provisional diagnosis was community-acquired through inhibition of the enzyme, guany- pneumonia, and cefuroxime and erythromcyin late cyclase. The case report presented were initiated. The hypoxaemia worsened, here demonstrates a beneficial haemody- necessitating intubation and mechanical venti- namic eect of continuous infusion of lation on the following day. Sputum and blood methylene blue during sepsis. These find- samples grew no pathogens, and a ventilation- ings could be extrapolated to other pa- perfusion scan indicated no pulmonary embo- tients or prompt additional research. lism. To attempt to improve ventilation, a chest tube was placed which evacuated ap- Keywords: methylene blue, nitric oxide, septic shock proximately 2.5 litres of a greenish-brown odourless liquid, which subsequently grew Candida albicans and an unidentified yeast. Nitric oxide has recently been implicated as a The patient was transferred to this institution potential mediator of both the peripheral after nine days of mechanical ventilation.
    [Show full text]
  • Globalhealth Precision State
    2018 Formulary Drug List For State, Education, and Local Government Employees GlobalHealth, Inc. 701 NE 10th Street, Suite 300 Oklahoma City, OK 73104-5403 MSTDF18 Lists Updated 11/2017 www.GlobalHealth.com/state HELPFUL NUMBERS Plan Issuer: Medication Prior Authorizations: GlobalHealth, Inc. [email protected] PO Box 2393 918.878.7361 Oklahoma City, OK 73101-2393 Mail Claims to: GlobalHealth Customer Care, Language Magellan Rx Management, LLC Assistance, and Disease Management: PO Box 85042 [email protected] Richmond, VA 23261-5042 405.280.5600 (local) 1.877.280.5600 (toll-free) Mail Order Pharmacy: 711 (TTY) Magellan Rx Management, LLC Monday – Friday, 9 a.m. – 5 p.m. Central 1.800.424.1789 (toll-free) www.GlobalHealth.com/state 711 (TTY) P.O. Box 620968 Behavioral Health and Substance Use: Orlando, FL 32862 [email protected] 405.280.5600 (local) 24/7 Nurse Help Line: 1.877.280.5600 (toll-free) Information Line 711 (TTY) 1.877.280.2993 (toll-free) Monday – Friday, 9 a.m. – 5 p.m. Central www.GlobalHealth.com/state GlobalHealth Compliance Officer: 1.877.280.5852 (toll-free) Pharmacy Benefits Manager: 405.280.5852 Magellan Rx Management, LLC [email protected] Customer Service 1.800.424.1789 (toll-free) GlobalHealth Privacy Officer: 711 (TTY) 405.280.5524 [email protected] i IMPORTANT INFORMATION This formulary applies to Members who enrolled through the State, Education, and Local Government employees Plan. Member Materials Your comprehensive Member handbook has three booklets. Each one has a different purpose. These documents are important legal documents. Keep them in a safe place.
    [Show full text]
  • Orange Book Cumulative Supplement 11 November 2020
    CUMULATIVE SUPPLEMENT 11 NOVEMBER 2020 APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 40th EDITION Department of Health and Human Services Food and Drug Administration Office of Medical Products and Tobacco Center for Drug Evaluation and Research Office of Generic Drugs Office of Generic Drug Policy 2020 Prepared By Food and Drug Administration Office of Medical Products and Tobacco Center for Drug Evaluation and Research Office of Generic Drugs Office of Generic Drug Policy APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS th 40 EDITION Cumulative Supplement 11 November 2020 CONTENTS PAGE Contents 1.0 INTRODUCTION .............................................................................................................................. v 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT ........................................................................ vi 1.2 CUMULATIVE SUPPLEMENT CONTENT ...................................................................................... vi 1.3 APPLICANT NAME CHANGES ...................................................................................................... vii 1.4 LEVOTHYROXINE SODIUM ........................................................................................................... ix 1.5 AVAILABILITY OF THE EDITION .................................................................................................... x 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST ................................ xi 1.7 CUMULATIVE SUPPLEMENT LEGEND .......................................................................................
    [Show full text]
  • Haloperidol Metabolites Elisa Kit Instructions Product #102119 & 102116 Forensic Use Only
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology HALOPERIDOL METABOLITES ELISA KIT INSTRUCTIONS PRODUCT #102119 & 102116 FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Haloperidol Metabolites in human urine, blood, oral fluid. DESCRIPTION Neogen Corporation’s Haloperidol Metabolites ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one- step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug-enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the diluted drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed 3 times to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of Red Stop Solution.
    [Show full text]
  • Drugs Which Can Affect Near Vision: a Useful List
    Drugs Which Can Affect Near Vision: A Useful List Joanne L. Smith B.Sc., Ph.Phm.* J. Raymond Buncic, M.D., F.R.C.S.(C)t ABSTRACT This paper documents a list of drugs that cause problems with near vision, by virtue of effects on accommodation, occasionally refractive error and diplopia. It is meant as a reference aid to the clinician when confronted with problems of focusing on near objects or print. There are many drugs that have been reported to interfere with near or reading vision, producing blurring, decreased accommodation and diplopia. This paper lists the drugs that have been reported in the literature to produce symptoms which interfere with near vision. Case reports for the listed drugs vary greatly from many to few. The drugs have been divided into the following categories: those causing (A) blurring at near, (B) diplopia and (C) induced myopia. Those drugs which only rarely cause these symptoms have been omitted. From the Departments of Pharmacy* and Ophthalmologyt, The Hospital For Sick Children, Toronto, Ontario, Canada Requests for reprints should be addressed to: Dr. J. Raymond Buncic, Department of Ophthalmology, The Hospital For Sick Children, 555 University Ave., Toronto, Ontario, Canada M5G lX8 TABLE 1 DRUGS COMMONLY CAUSING DIFFICULTY WITH FOCUSING AT NEAR OR BLURRED VISION. DRUG INCIDENCE REFERENCE Antipsychotics Chlorpromazine 14-23 8 Clozapine 5 8,14 Fluphenazine 1.2-4.3 8 Haloperidol 6.8-16 8 Loxapine 12,14 Perphenazine 7.4-17.8 8 Pimozide 20 8 Risperidone 1-2%, >/= 10% 11 Thioridazine 0.6-18 8 Thiothixene 20 8
    [Show full text]